Navigation Links
Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann 'Hot Topics in Therapeutics' Roundtable Conference
Date:2/7/2011

EAST NORRITON, Pa., Feb. 7, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion, will present at the upcoming 13th Annual BIO CEO & Investor Conference on Monday, February 14, 2011, at 2:00 p.m. EST.  Dr. Nichtberger will also participate in a panel discussion titled "IPO Window-Creaking Open or Wide Open?" the following day on Tuesday, February 15, 2011, at 1:30 p.m. EST.  


Dr. Nichtberger will also be presenting at the upcoming Leerink Swann "Hot Topics in Therapeutics" Roundtable Conference on Wednesday, February 16, 2011, at 9:35 a.m. EST.  Dr. Nichtberger will also participate in the Emerging Platforms panel discussion at 10:45 a.m. EST that same day.  


Replays of both webcasts will be available in the Investors section of the Company's at www.tengion.com.  Investors interested in listening to any live webcast are advised to log on before the start time in order to download any required software.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical program is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates. For more information, please visit www.tengion.com.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
2. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
3. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
4. Tengion Appoints A. Brian Davis Chief Financial Officer
5. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
6. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
7. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
8. Tengion Announces Second Closing of Series C Financing
9. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
10. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
11. Celtic Pharma Announces Presentation of Preclinical Data at the 69th Annual Meeting of the AAD in New Orleans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017   Sienna Biopharmaceuticals, Inc. , a ... announced that Richard Peterson will join the ... Peterson, who brings more than two decades of ... who is retiring at the end of April but ... Peterson joins Sienna from Novan, Inc., where he served ...
(Date:3/23/2017)... -- Research and Markets has announced the addition ... their offering. ... The Global Market for Bioproducts Should Reach $714.6 ... CAGR of 8.9%, This research report quantifies ... major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
(Date:3/23/2017)... According to a report by Transparency Market Research (TMR), ... the presence of a large pool of participants; however, only a ... Sigma-Aldrich, compete with each other in this market. With Proliant being ... of this market in 2016.  ... As of now, a large number of vendors are ...
Breaking Biology Technology:
(Date:2/24/2017)...  EyeLock LLC, a leader of iris-based identity ... biometric solution on the latest Qualcomm® Snapdragon™ 835 ... World Congress 2017 (February 27 – March ... 3, Stand 3E10. The Snapdragon ... platform—a combination of hardware, software and biometrics ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
Breaking Biology News(10 mins):